Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karsten Schrör

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Seminars in Vascular Medicine|June 17, 2004
Antithrombotic drugs in vascular medicine: a historical perspectiveKarsten Schrör
Medizinische Klinik (Munich, Germany : 1983)|October 19, 2004
[Current pharmacological principles to inhibit platelet function and their clinical implications. Focus on clopidogrel]Karsten Schrör
Diabetes, Obesity & Metabolism|August 16, 2002
The pharmacology of cilostazolKarsten Schrör
Best Practice & Research. Clinical Gastroenterology|November 30, 2011
Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancerKarsten Schrör
Thrombosis and Haemostasis|October 17, 2012
'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - a hypothesis that remains unprovenKarsten Schrör
Paediatric Drugs|May 26, 2007
Aspirin and Reye syndrome: a review of the evidenceKarsten Schrör
MMW Fortschritte Der Medizin|December 15, 2011
[Essential acetylsalicylic acid: over 100 years old and still good for surprises (interview by Dr. med. Jochen Aumiller)]Karsten Schrör
Circulation Research|January 31, 2009
Cyclooxygenase-2-derived prostaglandin F2alpha: an endothelium-derived contractile factor acting independently of other endothelium-derived contractile factors via vascular thromboxane receptorsKarsten Schrör
Pharmazie in Unserer Zeit|July 3, 2009
[100 years of successful drug discovery. The history of aspirin]Karsten Schrör
Thrombosis and Haemostasis|June 19, 2015
Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?Thomas Hohlfeld, Karsten Schrör
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Seminars in Vascular Medicine|June 17, 2004
Antithrombotic drugs in vascular medicine: a historical perspectiveKarsten Schrör
Medizinische Klinik (Munich, Germany : 1983)|October 19, 2004
[Current pharmacological principles to inhibit platelet function and their clinical implications. Focus on clopidogrel]Karsten Schrör
Diabetes, Obesity & Metabolism|August 16, 2002
The pharmacology of cilostazolKarsten Schrör
Best Practice & Research. Clinical Gastroenterology|November 30, 2011
Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancerKarsten Schrör
Thrombosis and Haemostasis|October 17, 2012
'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - a hypothesis that remains unprovenKarsten Schrör
Paediatric Drugs|May 26, 2007
Aspirin and Reye syndrome: a review of the evidenceKarsten Schrör
MMW Fortschritte Der Medizin|December 15, 2011
[Essential acetylsalicylic acid: over 100 years old and still good for surprises (interview by Dr. med. Jochen Aumiller)]Karsten Schrör
Circulation Research|January 31, 2009
Cyclooxygenase-2-derived prostaglandin F2alpha: an endothelium-derived contractile factor acting independently of other endothelium-derived contractile factors via vascular thromboxane receptorsKarsten Schrör
Pharmazie in Unserer Zeit|July 3, 2009
[100 years of successful drug discovery. The history of aspirin]Karsten Schrör
Thrombosis and Haemostasis|June 19, 2015
Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?Thomas Hohlfeld, Karsten Schrör
Pageof 11